View Older Stories
-
Insulet recalls 7 million Omnipod insulin pumps due to leakage risk
-
William Blair Assumes Insulet Corporation (PODD) at Outperform
-
Benchmark Reiterates Buy Rating on Insulet Corporation (PODD)
-
RBC sees over 80% upside to its price target for this medical stock
-
Insulet Corporation (PODD) PT Lowered to $250 at Truist Securities, 'Elite Growth Profile Looking More & More Mispriced'
-
Insulet Corporation (PODD) PT Lowered to $280 at RBC Capital, 'Best-in-class Financial Profile Intact'
-
Insulet Corporation (PODD) PT Lowered to $210 at Oppenheimer
-
Insulet Corporation (PODD) PT Lowered to $200 at Bernstein SocGen Group, 'shares fall; what now?'
-
Insulet Corporation (PODD) PT Lowered to $260 at BTIG
-
Insulet (PODD) Tops Q1 EPS by 22c
-
Insulet begins pivotal trial for fully closed-loop diabetes system
-
Rothschild Redburn Downgrades Insulet Corporation (PODD) to Neutral
-
Q1 MedTech quarterly preview: BTIG
-
Citi Downgrades Insulet Corporation (PODD) to Neutral
-
INSULET recalls specific Omnipod 5 pods due to insulin leak risk
-
Insulet reports positive results for closed-loop diabetes system
-
Piper Sandler: 'When Will Things Turn in Med Tech and What Names to Own Now?'
-
Insulet Corporation (PODD) PT Lowered to $330 at Bernstein
-
Insulet Corporation (PODD) PT Lowered to $300 at Oppenheimer
-
Insulet Corporation (PODD) PT Lowered to $435 at Canaccord Genuity
-
BTIG Reiterates Buy Rating on Insulet Corporation (PODD)
-
Insulet (PODD) Misses Q4 EPS by 2c
-
Insulet launches Omnipod 5 insulin system in Middle East
-
TD Cowen Assumes Insulet Corporation (PODD) at Hold, 'Leading, But Others Catching Up'
-
Barclays Downgrades Insulet Corporation (PODD) to Underweight
-
Barclays Downgrades DexCom (DXCM) to Underweight
-
Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
-
UBS Reiterates Buy Rating on Insulet Corporation (PODD)
-
Evercore ISI Starts Insulet Corporation (PODD) at Outperform, 'Leading the Tubeless Revolution in Insulin Delivery
-
Bernstein Shares Takeaways From the 5th Annual Diabetes Disruptor Conference
-
Insulet expands Pod recycling program nationwide across US
-
TD Cowen Reiterates Buy Rating on Insulet Corporation (PODD)
-
Insulet Corporation's (PODD) Competitive Moat Is Underappreciated - Analyst
-
Insulet Corporation (PODD) PT Raised to $432 at Canaccord Genuity
-
Insulet Corporation (PODD) PT Raised to $432 at Canaccord Genuity
-
Bernstein on Insulet Corporation (PODD): 'We See Plenty of Upside Potential from Here'
-
Insulet's (PODD) 'Competitive Moat Likely Underappreciated' - UBS
-
Insulet Corporation (PODD) PT Raised to $386 at Leerink Partners
-
Insulet Corporation (PODD) PT Raised to $412 at Truist Securities
-
Insulet Corporation (PODD) PT Raised to $380 at BTIG
-
Insulet Corporation (PODD) PT Raised to $385 at Raymond James
-
Insulet projects 20% revenue growth through 2028 at investor day
-
Buy this stock into tomorrow's Analyst Day: UBS
-
UBS Upgrades Insulet Corporation (PODD) to Buy
-
Insulet Corporation (PODD) PT Raised to $400 at Jefferies
-
BTIG Reiterates Buy Rating on Insulet Corporation (PODD)
-
Insulet (PODD) Tops Q3 EPS by 10c
-
Stifel Resumes Insulet Corporation (PODD) at Buy
-
Insulet Corporation (PODD) PT Raised to $399 at Canaccord Genuity
-
Insulet partners with Pantone to create Omnipod Mango color

